Table 5.
Ratio (95% confidence intervals) of the logged mean CVF cathelicidin concentration in cases and controls (cervical shortening, preterm birth and maternal/fetal outcomes) overall, and stratified by gestation at sampling in high risk women.
| Outcome | N (overall) | Overall | Ratio of cathelicidin concentration cases: controls* | |||
|---|---|---|---|---|---|---|
| Gestation category (weeks+days) | ||||||
| 10–13+6 | 14–15+6 | 16–19+6 | 20–24 | |||
| Cervical shortening < 25 mm | 321 | 1.26 (0.96–1.65) | 1.28 (0.82–1.99) | 1.45 (0.89–2.38) | 1.24 (0.91–1.70) | 1.26 (0.85–1.87) |
| sPTB < 37 w | 338 | 1.32 (1.01–1.72) | 1.26(0.85–1.88) | 1.85 (1.18–2.92) | 1.30 (0.94–1.80) | 1.14 (0.75–1.72) |
| sPTB < 34 w | 338 | 1.17 (0.83–1.65) | 1.10 (0.65–1.84) | 1.88 (0.89–3.98) | 1.19 (0.78–1.80) | 1.09 (0.61–1.93) |
| PPROM | 331 | 1.26 (0.90–1.78) | 1.01 (0.61–1.65) | 1.94 (1.06–3.54) | 1.35 (0.89–2.03) | 1.32 (0.76–2.28) |
| Objective infection | 338 | 1.11 (0.82–1.51) | 1.03 (0.64–1.67) | 1.07(0.64–1.79) | 1.29 (0.89–1.88) | 1.28 (0.80–2.05) |
| Fetal adverse outcome | 338 | 0.94 (0.71–1.26) | 0.78 (0.50–1.23) | 1.14 (0.71–1.83) | 1.15 (0.82–1.62) | 0.83 (0.53–1.29) |
Values in bold are statistically significant at p < 0.05.
*Ratio adjusted for maternal age, gestation at sampling, ethnicity, BMI, smoking and inter-plate pooled elafin concentration.